AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32250470 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 24
Study 35325102 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 2245
Study 35325102 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin users with AFF
Number of subjects: 2245
Study 35325102 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without AFF
Number of subjects: 2245
Study 35325102 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not using digoxin
Number of subjects: 2245
Study 35325102 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin users not in AFF
Number of subjects: 2245
Study 32331021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/d (flexible dosing)
Number of subjects: 2472
Study 32331021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 2472
Study 32331021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/d
Number of subjects: 2472
Study 32331021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2472
Study 35842109 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic video describing CRC and screening (Arm 2)
Number of subjects: 5280
Study 35842109 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice video showing advantages and disadvantages of FIT, s-DNA FIT, and colonoscopy (Arm 3)
Number of subjects: 5280
Study 35842109 — intervention group
Group type: COMPARATOR
Intervention: No video at all (Arm 1)
Number of subjects: 5280
Study 34684474 — intervention group
Group type: EXPERIMENTAL
Intervention: DUET intervention (web-based lifestyle intervention for 6 months)
Number of subjects: 56
Study 34684474 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 56
Study 34753334 — intervention group
Group type: EXPERIMENTAL
Intervention: small-group reading intervention with anxiety management instruction (RANX)
Number of subjects: 128
Study 34753334 — intervention group
Group type: EXPERIMENTAL
Intervention: small-group reading intervention with math fact practice (RMATH)
Number of subjects: 128
Study 34753334 — intervention group
Group type: COMPARATOR
Intervention: business-as-usual (BAU)
Number of subjects: 128
Study 34753334 — intervention group
Group type: EXPERIMENTAL
Intervention: RANX
Number of subjects: 128
Study 32815418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation as an adjunct to cardiac surgery
Number of subjects: 0
Study 32815418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ablation)
Number of subjects: 0
Study 35114511 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing the HNSE
Number of subjects: 14
Study 35114511 — intervention group
Group type: COMPARATOR
Intervention: Not wearing the HNSE
Number of subjects: 14
Study 33709997 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT program with brief motivational intervention and referral to specialized treatment
Number of subjects: 200
Study 33709997 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving two leaflets regarding alcohol use and study protocol
Number of subjects: 200
Study 33725776 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital physiotherapy (daily post-operative physiotherapy intervention including individualized mobilization, breathing exercises, ambulation with or without a walking aid)
Number of subjects: 34
Study 33725776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physiotherapy treatment)
Number of subjects: 34
Study 33725776 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital physiotherapy
Number of subjects: 34
Study 33725776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 32051297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX‐4
Number of subjects: 0
Study 32051297 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX‐4
Number of subjects: 0
Study 34714938 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (PGE1; 25 μg)
Number of subjects: 1580
Study 34714938 — intervention group
Group type: COMPARATOR
Intervention: Slow-release dinoprostone (PGE2; 10 μg)
Number of subjects: 1580
Study 34931602 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine
Number of subjects: 1510
Study 34931602 — intervention group
Group type: COMPARATOR
Intervention: levetiracetam
Number of subjects: 1510
Study 34931602 — intervention group
Group type: COMPARATOR
Intervention: zonisamide
Number of subjects: 1510
Study 34931602 — intervention group
Group type: EXPERIMENTAL
Intervention: valproate
Number of subjects: 1510
Study 33627245 — intervention group
Group type: EXPERIMENTAL
Intervention: MG1111
Number of subjects: 515
Study 33627245 — intervention group
Group type: COMPARATOR
Intervention: VarivaxTM
Number of subjects: 515
Study 33627245 — intervention group
Group type: COMPARATOR
Intervention: MG1111 and VarivaxTM
Number of subjects: 515
Study 33015194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 257
Study 33015194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia prediction model
Number of subjects: 257
Study 33181631 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic eyes
Number of subjects: 114
Study 33181631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudophakic eyes
Number of subjects: 114
Study 33181631 — intervention group
Group type: COMPARATOR
Intervention: Normal eyes
Number of subjects: 114
Study 34469399 — intervention group
Group type: EXPERIMENTAL
Intervention: SSP‐App program (experimental group)
Number of subjects: 107
Study 34469399 — intervention group
Group type: COMPARATOR
Intervention: No experimental treatment program (control group)
Number of subjects: 107
Study 34144460 — intervention group
Group type: EXPERIMENTAL
Intervention: Early care (EC) with follow-up in first seizure clinic (FSC) within 3 weeks
Number of subjects: 52
Study 34144460 — intervention group
Group type: COMPARATOR
Intervention: Late care (LC) with follow-up in FSC after 4 months
Number of subjects: 52
Study 34144460 — intervention group
Group type: COMPARATOR
Intervention: Children with febrile seizures (FS)
Number of subjects: 52
Study 36152481 — intervention group
Group type: EXPERIMENTAL
Intervention: General-digital-alteration label
Number of subjects: 872
Study 36152481 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-warning label
Number of subjects: 872
Study 36152481 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific-weight label
Number of subjects: 872
Study 36152481 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial features/cosmetic label
Number of subjects: 872
Study 36152481 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 872
Study 34162019 — intervention group
Group type: EXPERIMENTAL
Intervention: Unani formulations
Number of subjects: 82
Study 34162019 — intervention group
Group type: COMPARATOR
Intervention: Control (PUVAsol)
Number of subjects: 82
Study 33809996 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Glutamine supplementation (Gln) with physical exercises (PE + Gln)
Number of subjects: 44
Study 33809996 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Glutamine supplementation (Gln) without physical exercises (NPE + Gln)
Number of subjects: 44
Study 33809996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 44
Study 33809996 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Glutamine supplementation (Gln)
Number of subjects: 44
Study 32134713 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (250 mg tablet)
Number of subjects: 15
Study 32134713 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (0.05 mg/day transdermal patch)
Number of subjects: 15
Study 32134713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35263341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (music & ABS; n = 39)
Number of subjects: 163
Study 35263341 — intervention group
Group type: EXPERIMENTAL
Intervention: Music‐alone (n = 36)
Number of subjects: 163
Study 35263341 — intervention group
Group type: EXPERIMENTAL
Intervention: ABS‐alone (n = 41)
Number of subjects: 163
Study 35263341 — intervention group
Group type: COMPARATOR
Intervention: Pink noise (control; n = 47)
Number of subjects: 163
Study 35010287 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training combined with flexibility training (CT)
Number of subjects: 3
Study 35010287 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training (MT)
Number of subjects: 3
Study 35010287 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 3
Study 35798893 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 1012
Study 35798893 — intervention group
Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 1012
Study 35709465 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy
Number of subjects: 480
Study 35709465 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone (standard therapy)
Number of subjects: 480
Study 35709465 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin induction chemotherapy
Number of subjects: 480
Study 33092573 — intervention group
Group type: EXPERIMENTAL
Intervention: Op‐reha Guide (specialised rehabilitation)
Number of subjects: 135
Study 33092573 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation (control group)
Number of subjects: 135
Study 33046233 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular reshaping with a beating heart implant
Number of subjects: 38
Study 33046233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implant)
Number of subjects: 38
Study 34066784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-FOLFIRI
Number of subjects: 84
Study 34066784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-FOLFOX
Number of subjects: 84
Study 32756952 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI in women with PCOS
Number of subjects: 1561
Study 32756952 — intervention group
Group type: COMPARATOR
Intervention: Increasing BMI in ovulatory controls (OVAs)
Number of subjects: 1561
Study 32756952 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI in PCOS
Number of subjects: 1561
Study 32756952 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface area (BSA)
Number of subjects: 1561
Study 32756952 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1561
Study 33895221 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 80
Study 33895221 — intervention group
Group type: COMPARATOR
Intervention: Retrolaminar Block (RLB)
Number of subjects: 80
Study 34587986 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian cardioprotective diet and nuts
Number of subjects: 0
Study 34587986 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32897359 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccination
Number of subjects: 8319
Study 32897359 — intervention group
Group type: COMPARATOR
Intervention: Health check-up
Number of subjects: 8319
Study 35786597 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (NIVO) first-line therapy in combination with chemotherapy
Number of subjects: 0
Study 35786597 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (NIVO) third-line or later monotherapy
Number of subjects: 0
Study 32068914 — intervention group
Group type: EXPERIMENTAL
Intervention: Licogliflozin 10 mg
Number of subjects: 125
Study 32068914 — intervention group
Group type: EXPERIMENTAL
Intervention: Licogliflozin 50 mg
Number of subjects: 125
Study 32068914 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg)
Number of subjects: 125
Study 35858190 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth application
Number of subjects: 0
Study 35858190 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 34008203 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donors (n = 2,600)
Number of subjects: 5100
Study 34008203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (n = 2,500)
Number of subjects: 5100
Study 34008203 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive healthy donors (n = 56)
Number of subjects: 5100
Study 34008203 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (n = 595)
Number of subjects: 5100
Study 35622105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Sequential Pneumatic Compression (ISPC) device
Number of subjects: 50
Study 35622105 — intervention group
Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 50
Study 34108173 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-supported, interactive mHealth platform for self-management of dementia risk factors
Number of subjects: 2400
Study 34108173 — intervention group
Group type: COMPARATOR
Intervention: Static control platform
Number of subjects: 2400
Study 34318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium preemptive analgesia
Number of subjects: 70
Study 34318635 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin suppository (0.1 g/suppository)
Number of subjects: 70
Study 33071153 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-activated NiTi archwires at 35°C
Number of subjects: 54
Study 33071153 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-activated NiTi archwires at 37°C
Number of subjects: 54
Study 35279835 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 0
Study 35279835 — intervention group
Group type: COMPARATOR
Intervention: PCSK9-inhibiting monoclonal antibodies
Number of subjects: 0
Study 33230873 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm height abutment during surgical stage (Group A)
Number of subjects: 29
Study 33230873 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm height abutment during surgical stage (Group B)
Number of subjects: 29
Study 33230873 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm height abutment after 2 months (Group C)
Number of subjects: 29
Study 33097016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash Transfers (CTs)
Number of subjects: 2909
Study 34520608 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol (3 mM)
Number of subjects: 18
Study 34520608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 34749739 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily on top of standard of care for 28 days
Number of subjects: 28
Study 34749739 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only for 28 days
Number of subjects: 28
Study 35440808 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure in the evening
Number of subjects: 252
Study 35440808 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure in the morning
Number of subjects: 252
Study 35440808 — intervention group
Group type: EXPERIMENTAL
Intervention: Office blood pressure before treatment
Number of subjects: 252
Study 35440808 — intervention group
Group type: EXPERIMENTAL
Intervention: Office blood pressure in the on-treatment follow-up period
Number of subjects: 252
Study 34656663 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided CVAD insertion
Number of subjects: 2786
Study 34656663 — intervention group
Group type: COMPARATOR
Intervention: Left-sided CVAD insertion
Number of subjects: 2786
Study 35546563 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 110
Study 35546563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 32183902 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component implementation support strategy for PA4E1 program
Number of subjects: 38
Study 32183902 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data collection from Physical Education teachers, in-School Champions, students
Number of subjects: 38
Study 32183902 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection through semi-structured interviews and focus groups
Number of subjects: 38
Study 35580165 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐I+Light
Number of subjects: 101
Study 35580165 — intervention group
Group type: COMPARATOR
Intervention: TAU+
Number of subjects: 101
Study 33632085 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-18a and PD-L1 levels in HPV-positive cervical cancer patients (observation group)
Number of subjects: 382
Study 33632085 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microecology in HPV-positive cervical cancer patients (observation group)
Number of subjects: 382
Study 33632085 — intervention group
Group type: COMPARATOR
Intervention: Vaginal microecology in healthy women (control group)
Number of subjects: 382
Study 33632085 — intervention group
Group type: COMPARATOR
Intervention: miR-18a and PD-L1 levels in healthy women (control group)
Number of subjects: 382
Study 33632085 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-18a and PD-L1 levels in patients at stage III (observation group)
Number of subjects: 382
Study 33632085 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic value of miR-18a and PD-L1
Number of subjects: 382
Study 32245274 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive SRH/family planning intervention
Number of subjects: 2100
Study 35075723 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical/nasal administration of a probiotic assemblage (PA) of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A
Number of subjects: 24
Study 35075723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Three potentially neuroprotective drugs
Number of subjects: 0
Study 34933930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32320144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 0
Study 32320144 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 0
Study 36502286 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (AMEx)
Number of subjects: 100
Study 36502286 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (PMEx)
Number of subjects: 100
Study 36502286 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (CON)
Number of subjects: 100
Study 33119790 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 74
Study 33119790 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 74
Study 32251223 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (5 days/week for 4 weeks)
Number of subjects: 56
Study 32251223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 56
Study 33741876 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer-related injuries in players aged 12 to 18
Number of subjects: 0
Study 33741876 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer-related injuries in players aged 6 to 11
Number of subjects: 0
Study 33741876 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer-related injuries in players aged 19 to 34
Number of subjects: 0
Study 32106869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (PO) administration of diclofenac
Number of subjects: 38
Study 32106869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of diclofenac
Number of subjects: 38
Study 32106869 — intervention group
Group type: COMPARATOR
Intervention: Undesired route (either PO or IM)
Number of subjects: 38
Study 35689284 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee sleeve worn for 6 weeks at least 1 hour daily (Sleeve Group, n=9)
Number of subjects: 31
Study 35689284 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=9) did not wear the knee sleeve
Number of subjects: 31
Study 35129469 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1200 mg twice-daily for up to 5 days postoperatively
Number of subjects: 33
Study 35129469 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 33
Study 32880953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Training Group (DBT‐ST), n=16
Number of subjects: 31
Study 32880953 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TaU), n=15
Number of subjects: 31
Study 36177827 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SpA) with clonidine
Number of subjects: 135
Study 36177827 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EDA)
Number of subjects: 135
Study 36177827 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SpA)
Number of subjects: 135
Study 33853609 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative mode
Number of subjects: 21
Study 33853609 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive mode
Number of subjects: 21
Study 33853609 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-active mode
Number of subjects: 21
Study 33183673 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape Juice (GJ)
Number of subjects: 12
Study 33183673 — intervention group
Group type: COMPARATOR
Intervention: Control (WB)
Number of subjects: 12
Study 33183673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 32367254 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and dietary intervention
Number of subjects: 504
Study 32367254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study 32183250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 32183250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32183250 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 36882134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert during individual patient encounters
Number of subjects: 2211
Study 36882134 — intervention group
Group type: EXPERIMENTAL
Intervention: Message about multiple patients between encounters
Number of subjects: 2211